Terbutaline
Brethine (terbutaline) is a small molecule pharmaceutical. Terbutaline was first approved as Brethine on 1982-01-01. It is used to treat asthma in the USA. The pharmaceutical is active against beta-2 adrenergic receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Brethine (generic drugs available since 2001-06-26, discontinued: Brethaire, Bricanyl)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Terbutaline sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BRETHINE | ANI PHARMS | N-017849 RX | 1982-01-01 | 2 products, RLD |
Show 5 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| terbutaline sulfate | ANDA | 2023-05-23 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| asthma | EFO_0000270 | D001249 | J45 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
R: Respiratory system drugs
— R03: Drugs for obstructive airway diseases
— R03A: Adrenergics, inhalants
— R03AC: Selective beta-2-adrenoreceptor agonist inhalants
— R03AC03: Terbutaline
— R03C: Adrenergics for systemic use
— R03CC: Selective beta-2-adrenoreceptor agonists, systemic
— R03CC03: Terbutaline
— R03CC53: Terbutaline, combinations
HCPCS
Code | Description |
|---|---|
| J3105 | Injection, terbutaline sulfate, up to 1 mg |
| J7680 | Terbutaline sulfate, inhalation solution, compounded product, administered through dme, concentrated form, per milligram |
| J7681 | Terbutaline sulfate, inhalation solution, compounded product, administered through dme, unit dose form, per milligram |
Clinical
Clinical Trials
16 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | 1 | 2 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | — | — | 1 | 1 | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | 1 | — | 1 |
| Hyperhidrosis | D006945 | HP_0000975 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Secondary parkinson disease | D010302 | EFO_1001175 | G21 | — | 2 | — | — | — | 2 |
| Rem sleep behavior disorder | D020187 | EFO_0007462 | G47.52 | — | 2 | — | — | — | 2 |
| Dementia | D003704 | F03 | 1 | 1 | — | — | — | 1 | |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | 1 | — | — | — | 1 |
| Carotid stenosis | D016893 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lower urinary tract symptoms | D059411 | EFO_0008008 | — | — | — | — | 1 | 1 | |
| Nocturia | D053158 | R35.1 | — | — | — | — | 1 | 1 | |
| Urinary retention | D016055 | HP_0000016 | R33 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TERBUTALINE |
| INN | terbutaline |
| Description | Terbutaline is a member of the class of phenylethanolamines that is catechol substuted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group. It has a role as a beta-adrenergic agonist, an EC 3.1.1.7 (acetylcholinesterase) inhibitor, an anti-asthmatic drug, a bronchodilator agent, a sympathomimetic agent, a tocolytic agent and a hypoglycemic agent. It is a member of phenylethanolamines and a member of resorcinols. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)(C)NCC(O)c1cc(O)cc(O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 23031-25-6 |
| RxCUI | 10368 |
| ChEMBL ID | CHEMBL1760 |
| ChEBI ID | 9449 |
| PubChem CID | 5403 |
| DrugBank | DB00871 |
| UNII ID | N8ONU3L3PG (ChemIDplus, GSRS) |
Target
Agency Approved
ADRB2
ADRB2
Organism
Homo sapiens
Gene name
ADRB2
Gene synonyms
ADRB2R, B2AR
NCBI Gene ID
Protein name
beta-2 adrenergic receptor
Protein synonyms
adrenergic, beta-2-, receptor, surface, adrenoceptor beta 2 surface, Beta-2 adrenoceptor, Beta-2 adrenoreceptor, catecholamine receptor
Uniprot ID
Mouse ortholog
Adrb2 (11555)
beta-2 adrenergic receptor (Q8BH38)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,294 documents
View more details
Safety
Black-box Warning
Black-box warning for: Terbutaline sulfate
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,758 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more